SVR after Treatment of HCV Genotype 1a with ABT-450/Ritonavir, Ombitasvir, and Dasabuvir is Enhanced by RBV in Noncirrhotic Patients and by Extension of Duration in Cirrhotic Patients

Article Information

DOI 
http://dx.doi.org/10.1177/155989771448015
Published By 
SAGE Publications
Print ISSN 
1559-8977
Online ISSN 
2155-756X
Copyright & Usage 
© 2014 MD Conference Express®

Author Information

  1. Brian Hoyle
  1. Gregory Everson, MD
    1. University of Colorado, Denver, Colorado, USA
View Full Text

Article usage

AbstractFullPDF
Apr 2015500
Jun 2015500
Jul 2015111
Aug 20154000
Sep 20153700
Oct 2015233
Nov 20153321
Total12365

Note: Article usage statistics are calculated and reported monthly.

Cited By...

  • No citing articles found.
Back to top

Tools

View Full Page PDF
Citation Tools
Email
SVR after Treatment of HCV Genotype 1a with ABT-450/Ritonavir, Ombitasvir, and Dasabuvir is Enhanced by RBV in Noncirrhotic Patients and by Extension of Duration in Cirrhotic Patients
Permalink: Copy
Linkedin Share Button del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo StumbleUpon logo

Table of contents

Cited By...

  • No citing articles found.

Keywords

Hepatology Clinical Trials Liver Conditions
Viral Infections
Hepatology Clinical Trials
Hepatology
Liver Conditions
Viral Infections